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Abstract: Genetic cardiomyopathies are characterized by changes in the function and structure of
the myocardium. The development of a novel in vitro model could help to better emulate healthy
and diseased human heart conditions and may improve the understanding of disease mechanisms.
In this study, for the first time, we demonstrated the generation of cardiac organoids using a triculture
approach of human induced pluripotent stem-cell-derived cardiomyocytes (hiPS-CMs)—from healthy
subjects and cardiomyopathy patients—human cardiac microvascular endothelial cells (HCMECs)
and human cardiac fibroblasts (HCFs). We assessed the organoids’ suitability as a 3D cellular model
for the representation of phenotypical features of healthy and cardiomyopathic hearts. We observed
clear differences in structure and beating behavior between the organoid groups, depending on the
type of hiPS-CMs (healthy versus cardiomyopathic) used. Organoids may thus prove a promising
tool for the design and testing of patient-specific treatments as well as provide a platform for safer
and more efficacious drug development.
Keywords: hiPSCs; cardiomyocytes; differentiation; 3D culture; organoids; in vitro disease modeling;
personalized medicine
1. Introduction
Presently, cardiovascular diseases (CVD) represent the main cause of death worldwide [1].
Cardiomyopathies (nongenetic and genetic)—a set of conditions that compromise the contractile
activity of the heart in affected patients—represent a highly relevant subset of CVD. The disease
mechanisms in genetic cardiomyopathy are extremely variable, making it difficult to establish a
universal efficacious treatment and causing a tremendous cost burden on healthcare systems [2].
The development of novel drugs and treatments is a long and expensive process, often involving
years or decades of research, potentially leading to ineffectual results [3,4]. Indeed, the efficacy and
safety of novel medications are first evaluated during a preclinical drug discovery process which is
typically performed in 2D cell cultures and subsequently in animal models. Unfortunately, both models
fail in adequately representing human physiological conditions and incur the risk of novel candidate
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failure [5–7]. Adverse events at a late stage of clinical trials can cause substantial temporal and financial
loss [8]. To overcome these limitations and to enhance the understanding of biological mechanisms
during the preclinical stage of the drug discovery process, a new concept based on culturing cells
in three dimensions (3D) has been suggested [9]. It is believed that 3D human organoid models
will eventually promote better understanding of human disease mechanisms, and help direct future
treatments towards personalized medicine [10–13].
The advances in human induced pluripotent stem cell (hiPSC) technology allow for in vitro disease
modeling and tissue regeneration research geared towards patient-specific treatments. They also give
rise to the possibility of developing functional human organoids to emulate a multitude of organ
systems and conditions more easily [14,15]. One key feature of hiPSCs is the capacity of the cells to retain
the patient genotype from which they were derived [16]. Lan et al. showed that cardiomyocytes (CMs)
differentiated from hiPSCs derived from a hypertrophic cardiomyopathy (HCM) patient containing
a gene mutation encoding for myosin heavy chain 7 (MYH7) retained the mutation and displayed
the HCM phenotype, which is characterized by cellular hypertrophy and abnormal calcium handling
activity as evidenced by irregular beating/arrhythmia [17]. We narrowed our research focus on a
missense mutation of MYH7 in exon 19 where a single point mutation (SNP) causes an amino acid
change from Arginine into Glutamine, referred to as Arg719Gln or R719Q-MYH7 mutation. Despite
being annotated as a benign mutation, this SNP has been known to play a role in the onset of HCM
causing sudden cardiac death [18,19].
Despite well-established chemically-defined methods to efficiently differentiate hiPSCs into
high quality cardiomyocytes (CMs), only few studies have so far investigated cardiac organoids for
mimicking the human heart and its functions [20–23]. Given the advances in reprogramming somatic
cells to obtain hiPSC lines reflecting patient-specific genome profiles and in differentiating hiPSCs into
cardiomyocytes (hiPSC-CMs) resembling the corresponding cardiac phenotypes, a multicellular 3D
bioengineered tissue construct strategy is deemed a promising approach for modeling the human
heart in vitro [24–26]. However, the myocardium also contains nonmyocyte cells, which play essential
roles in cardiac physiology and function. Cardiac fibroblasts and cardiac endothelial cells represent
the majority of nonmyocytes present in the adult heart [23,25]. Cardiac fibroblasts contribute to
tissue maintenance and remodeling through the synthesis of extracellular matrix (ECM) and directly
affect the electrical properties of the myocardium. Endothelial cells (ECs) regulate the contractile
state, survival, metabolism and rhythmicity of CMs through autocrine and paracrine signaling [26,27].
The combination of these three cells types, therefore, may have the potential to significantly improve
the cardiac research field through the development of human cardiac organoids. The latter can mimic
various heart developmental stages, and can be used not only as a reliable platform for drug screening
but also as a tool to imitate patient-specific cardiac conditions and assess the effectiveness of tailored
personalized treatments [12].
In this study, as a first step, we compared two chemically defined protocols for the differentiation
of hiPSCs into CMs. Two commercially available hiPSC lines, one obtained from a healthy patient
and one from an HCM-patient carrying an MYH7 mutation, were differentiated into CMs. hiPSC-CM
quality was assessed by the evaluation of cell morphology and beating intensity. The better-suited
protocol was chosen based on the quality of the hiPSC-CMs at harvesting day. The differentiated
cells were subsequently characterized in terms of cell population purity using flow cytometry and in
terms of differentiation status using quantitative gene expression analysis. Further optimization of
the culturing conditions for the creation of cardiac organoids containing CMs and nonmyocytes was
performed. We obtained highly contractile cardiac organoids consisting of hiPSC-CMs, human cardiac
microvascular endothelial cells (HCMECs) and human cardiac fibroblasts (HCFs) by seeding a mix of
corresponding single cell suspensions. The organoids containing either of the two hiPSC-derived CMs
(healthy and cardiomyopathy-associated) were then compared in terms of cell distribution, structural
integrity, differentiation status and calcium activity, in order to assess their capability of representing
the donors’ phenotypic features.
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2. Materials and Methods
Materials were purchased from Sigma Aldrich, unless stated otherwise.
2.1. Cell Culture
2.1.1. Human Cardiac Microvascular Endothelial Cells
Human Cardiac Microvascular Endothelial Cells (HCMECs) are primary cells isolated from human
heart tissue. HCMECs were purchased from ScienCell Research Laboratories (Carlsbad, USA) and
cultured in cell culture flasks precoated with 2 µg/cm2 Bovine Plasma Fibronectin (BPF) (#8248) diluted
in Endothelial Cell Medium (ECM) (#1001). The ECM was supplemented with 5% Fetal Bovine Serum
(#0025), 1% Endothelial Cell Growth Supplement (ECGS) (#1052) and 1% Penicillin-Streptomycin
solution (#0503).
2.1.2. Human Cardiac Fibroblast
Human Cardiac Fibroblasts (HCFs) are primary cells isolated from healthy adult human heart
tissue. Cryopreserved HCFs were purchased from Cell Application (San Diego, CA, USA) and cultured
in HCF Growth Medium (#316K-500).
2.1.3. Cor.4U Cardiomyocytes
Cor.4U Cardiomyocytes (Cor.4U-CMs) are commercially available human embryonic stem
cell-derived cardiomyocytes (hiPSC-CMs) containing a mix of 60% ventricular, 20% atrial, and 20%
nodal cells. One frozen cryovial (1 × 106 cells) was purchased from NCardia Stem Cell Expert (Leiden,
the Netherlands). Cor.4U-CMs were cultured as recommended by the manufacturer. Briefly, 1 × 106
Cor.4U-CMs were thawed and plated in a 25 cm2 culture flask (T25) (TPP Techno Plastic Products
AG, Trasadingen, Switzerland), precoated with 10 µg/mL Fibronectin (Sigma-Aldrich, #F1141) in
Dulbecco’s Phosphate Buffered Saline (DPBS) with Ca2+ and Mg2+ (Gibco, #14040-133) in Complete
Culture Medium (#Ax-M-HC250), supplemented with 2 µg/mL Puromycin (#Ax-M-PO-05). After 24 h
incubation, the medium was changed and the flask was kept in culture at 37 ◦C, 5% CO2. Forty-eight
hours post-thawing, the Cor.4U-CMs were dissociated using 0.05% Trypsin EDTA (Life Technologies,
#15400, Zug, Switzerland) and immediately used to generate triculture organoids.
2.1.4. Human Induced Pluripotent Stem Cell Lines
Two commercially available hiPSC lines were purchased from the European Bank of Induced
Pluripotent Stem Cells (EBiSC, Salisbury, UK). The Wellcome Trust Sanger Institute (WTSIi020-A)
line was derived from a healthy donor and the Uniklinik Köln (UKKi025-A) line originated from a
hypertrophic cardiomyopathy donor (see Table 1). All cell culture reagents for hiPSCs were purchased
from Stem Cell Technologies (Cologne, Germany), unless stated otherwise.
Table 1. Human induced pluripotent stem cell (hiPSC) lines obtained from the European Bank of
Induced Pluripotent Stem Cells (EBiSC).
hiPSC Line Gender Age Race Remarks
WTSIi020-A Female 40–44 Caucasian Derived from healthy donor
UKKi025-A Female 40–44 Caucasian
Derived from hypertrophic cardiomyopathy (HCM)
donor with MYH7 mutation. The mutation is a
heterozygous missense mutation of the β-myosin heavy
chain MYH7 gene located in exon 19, at chromosome
location 14q11.2. There is a change of the single
nucleotide sequence at position 2156 from G to A which
causes the exchange of a nonpolar amino acid for a
positively charged one (Arginine changed into
Glutamine) in codon 719.
Cells 2020, 9, 1733 4 of 19
Both cell lines were cultured in a six-well plate (TPP, Switzerland), precoated with 10 µg/mL
VitronectinXF (#07180) in CellAdhere dilution buffer (#07183). On seeding day, each cryovial was
thawed and seeded into two wells in 2 mL/well mTeSR1 complete medium (#85850) supplemented
with 10 µM Y-27632 (#72304).The latter is a ROCK pathway inhibitor that significantly enhances the
recovery of frozen stocks and improves hiPSCs attachment and growth in culture vessels. After 24 h at
37 ◦C with 5% CO2, the ROCKi medium was replaced with mTeSR1 complete medium, which was
replenished daily until about 70% confluency. Subculturing with a split ratio of 1:6 was done when
cell colonies presented as compact clusters with well-defined edges by using a nonenzymatic reagent,
ReLeSR (#05872). Cryopreservation was done using animal component-free medium, CryoStor CS10
(#07930), containing 10% DMSO.
2.2. Cardiomyocyte Differentiation
2.2.1. STEMdiff Differentiation Protocol
WTSIi020-A (passage no. ≥38) and UKKi025-A (passage no. ≥41) were cultured in mTeSR1
medium (StemCell Technologies, Vancouver, BC, Canada) in VitronectinXF-coated 12-well plates until
95% confluence. The STEMdiff Cardiomyocyte Differentiation Kit (StemCell Technologies, #05010) was
used to differentiate hiPSCs into CMs in eight days by following the manufacturer’s protocol. From day
8 to 15, the obtained hiPSC-CMs (WTSI-CMs and UKK-CMs) were maintained in culture, using the
STEMdiff Maintenance Kit (#05020), as recommended by the supplier. On day 15, cell harvesting
was performed by dissociating the hiPSC-CMs, using the STEMdiff Cardiomyocyte Dissociation Kit
(#05025) and a fraction of the cells was cryopreserved in STEMdiff Cardiomyocyte Freezing Medium
(#05030) at a cell density of 1 × 106 cells/mL. To reduce stress due to cell thawing and to improve
hiPSC-CMs recovery, STEMdiff Cardiomyocyte Support Medium (#05027) was applied for 24 h after
thawing and then replaced with STEMdiff Cardiomyocyte Maintenance Medium for long-term culture.
2.2.2. CDM3 Differentiation Protocol
WTSIi020-A (passage no. ≥38) and UKKi025-A (passage no. ≥41) were cultured and expanded in
six-well plates. At 70% confluence, the cells were split at a 1:4 ratio and replated in VitronectinXF-coated
12-well plates until about 85% confluence. CM differentiation was performed as described by
Burridge et al. 2014 [21]. Briefly, the cell medium was changed to CDM3, consisting of RPMI 1640
(11875, Life Technologies) supplemented with 500 µg/mL Oryza sativa-derived recombinant human
albumin (A0237, Sigma-Aldrich, 75 mg/mL stock solution in WFI H2O, stored at −20 ◦C) and 213 µg/mL
L-ascorbic acid 2-phosphate (Sigma-Aldrich, 64 mg/mL stock solution in WFI H2O, stored at −20 ◦C).
The medium was changed every other day (48 h). For the first 48 h post cell replating, CDM3 was
supplemented with 6 µM CHIR99021 (LC Laboratories). On day 2, the medium was changed to CDM3
supplemented with 2 µM Wnt-C59 (Selleck Chemicals). The medium was then again changed on day 4,
and every other day until day 15 using CDM3. Contracting cells were observed from day 7 onwards.
On day 15, both hiPSC-derived cardiomyocyte lines (WTSIi020-A-CMs and UKKi025-A-CMs) were
dissociated with TrypLE Express (1×) containing phenol red (ThermoFisher Scientific, #12605010) for
10 min at 37 ◦C and used for gene expression analysis (RT-qPCR), cell population analysis (FACS) and
triculture organoid formation. Day 15 dissociated cells were counted using a LUNA Automated Cell
Counter (Logos Biosystems, Villeneuve-d’Ascq, France) and a fraction of the cells was cryopreserved
at 1 × 106 cells per vial in CryoStor® CS10.
2.3. Flow Cytometry
WTSIi020-A-CMs and UKKi025-A-CMs were harvested on day 0 and 15 to evaluate the efficacy
of the differentiation protocol (CDM3) in producing hiPSC-CMs. The dissociated cells were directly
transferred to flow cytometry tubes (BD Biosciences) and stained with a live/dead discriminator using
1:1000 Zombie Aqua Dye (BioLegend, #423101). Samples were fixed with 4% PFA for 15 min and
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stored in FACs buffer, containing 2% FBS, 5mM EDTA, 0.01% Sodium Azide in PBS, at 4 ◦C for later
use. Before flow cytometry analysis, samples were permeabilized using a blocking buffer containing
20% FBS, 3% BSA, 0.2% Saponin in PBS for 10 min at RT. They were then stained using an antibody
solution containing 1% BSA and 0.1% Saponin in PBS, 1:600 mouse monoclonal IgG1 TNNT2 (cardiac
troponin T, clone 1G1, #MA5-17192) and rabbit monoclonal IgG OCT4 (Octamer-binding transcription
factor 4, clone T.631.9, #MA5-14845) primary antibodies (ThermoFisher Scientific, USA) for 1 h in the
dark at RT. Secondary antibody staining was performed with 1:600 dilutions of Alexa Fluor 488 and
Alexa Fluor 568 secondary antibodies (Life Technologies) for 30 min at RT. Samples were analyzed
using LSRFortessa (BD Biosciences) and FACSDiva Software. The resulting data was analyzed using
FlowJo v10 (TreeStar).
2.4. Real-Time Quantitative PCR Analysis
WTSIi020-A-CMs and UKKi025-A-CMs were collected at two differentiation time points, day 0 as
a control for pluripotent markers and day 15 to check the efficiency of the CM differentiation protocol.
Cor.4U-CMs (1 × 106) were also sampled and used as a positive control for cardiac markers. Samples
were lysed with RLT buffer (QIAGEN) and stored at −80 ◦C before proceeding with mRNA extraction.
RNA samples were obtained using RNeasy Mini Kit (QIAGEN, #74104). 100 ng RNA per sample were
reverse transcribed to 20 µL cDNA (1:1 reaction) using iScript Reverse Transcription Supermix (Bio-Rad,
#1708841). Quantitative gene expression analysis was performed using TaqMan Fast Universal PCR
Master Mix (2×), no AmpErase UNG (Applied Biosystems, #4366073), TaqMan Gene Expression
Assays (listed in Table 2) and an Applied Biosystems 7500 Fast Real-Time qPCR System. All reactions
were performed in triplicate and normalized using the 18S endogenous housekeeping gene. Relative
quantification of gene expression was performed using the ∆∆Ct method, where 2
−∆∆Ct was calculated
to obtain the expression fold change value of each gene.
Table 2. Taqman gene expression assays used to prove the efficiency of Chemically-Defined Medium 3
(CDM3) differentiation protocol through real-time quantitative polymerase chain reaction (RT-qPCR).
Gene Category Symbol Gene Name Taqman Primer ID
Housekeeping 18S Eukaryotic 18S rRNA Hs99999901_s1
Pluripotency
NANOG Nanog Homeobox Protein Hs02387400_g1
OCT4 (POU5F1) Octamer-binding Transcription Factor 4 Hs00999632_g1
SOX2 SRY (Sex determining Region Y)-box 2 Hs01053049_s1
KLF4 Kruppel Like Factor 4 Hs00359936_m1
MYC
V-Myc Avian Myelocytomatosis Viral
Oncogene Homolog
Hs00153408_m1
Cardiac Development NKX2.5 NK2 Homeobox 5 Hs00231763_m1
Cardiac Structure
TNNT2 Cardiac-specific Troponin Hs00165960_m1
MYH6 Myosin Heavy Chain 6 Hs00411908_m1
MYH7 Myosin Heavy Chain 7 Hs01110632_m1
2.5. Organoid Formation Technique
Triculture organoids were created by combining hiPSC-CMs (Cor.4U-CMs or WTSI-CMs or
UKK-CMs) with HCMECs and HCFs in a single-cell suspension at a physiological cell ratio of 3:5:2,
as suggested by Devalla and Passier [28]. Greiner HLA Terasaki 60-well plates (Sigma-Aldrich, #M6062)
were used to create the organoids utilizing a modified hanging drop protocol [5,29]. Approximately
100,000 cells in 20 µL cell suspension were pipetted into each well. Organoids were harvested after
three days and transferred to Poly-L-Lysine (Sigma-Aldrich, #P4707) precoated 12-well plates for
long-term culture (21 days).
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2.6. Cell and Organoid Immunofluorescence Staining
Cells were fixed with 4% PFA (Sigma) for 20 min at room temperature. They were permeabilized with
a solution of 0.2% saponin/20% FBS/3% BSA, and further stained with primary and secondary antibodies.
Organoids were harvested and immunofluorescence stained using the Visikol Histo Organoid
Protocol. Briefly, organoids were transferred to 12-well plates and fixed overnight (≤16 h) in 4% PFA
(Sigma Aldrich, Buchs, Switzerland). After fixation, they were transferred into a 0.05% sodium azide
solution in PBS for long-term storage before processing.
All antibodies used were purchased from ThermoFisher Scientific Zurich, Switzerland, and further
diluted in Visikol Antibody Buffer (Hampton, NJ, USA). Primary antibodies used were as follows:
mouse antihuman alpha sarcomeric actinin (1:300, #MA122863), goat antihuman cardiac troponin
(TNNT2, 1:300, #PA1-86820), rabbit antihuman vimentin (VIM, 1:300, #MA5-16409) and mouse
antihuman vascular cadherin (VeCADH, 1:300, #14-1449-82). DAPI solution (1 mg/mL, #62248) was
used as a nuclear label, diluted 500-fold in Visikol Antibody Buffer, and incubated for 5 min at 37 ◦C
between the application of the primary and secondary antibodies. Secondary antibodies used were as
follows: rabbit anti-goat Alexa Fluor 647 (#A27018), goat anti-rabbit Alexa Fluor 488 (#A11034) and goat
anti-mouse Alexa Fluor 568 (#A11004). Images were taken with a Leica SP8 confocal microscopy system.
2.7. Calcium Activity Monitoring Assay
Calcium activity in highly contractile cardiac organoids was assessed using the EarlyTox Cardiotoxicity
Kit (Molecular Devices). The kit contains a dye which binds to calcium ions as they enter the cell cytoplasm,
allowing for the measurement of changes in calcium concentrations. Briefly, Cor-Oids, WTS-Oids
and UKK-Oids were transferred to eight-well µ-slides (Ibidi—cells in focus, #80824), containing
100µL of medium and 100µL of prewarmed calcium dye per well, and incubated for 2 h at 37 ◦C.
The calcium activity within the organoids was observed using widefield microscopy and recorded for
90 s. The beating pattern of each organoid type was analyzed and plotted using Fiji- ImageJ v2.0.0.
The beating rates per minute (bpm) were calculated in Fiji- ImageJ v2.0.0 using the BAR plug-in, which
determines the peaks in the plotted organoid beating curves.
2.8. Statistical Analysis
FACS: the flow cytometry standard files obtained from the FACS analysis were processed using
FlowJo. Firstly, gating of the forward (FCS) versus side scatter (SCC) was determined. To determine
the live cell population, the singlets and zombie aqua dye negative events were selected. The Median
Fluorescence Intensity (MFI) over the differentiation time (day 0 vs day 15) in TNNT2 and OCT4 cells
was recorded, plotted and compared by a two-way ANOVA test using the GraphPad Prism 8 software.
All data are presented as mean ± standard error of the mean (SEM). A p-value ≤0.01 was deemed
statistically significant.
qPCR: 18S was selected as the housekeeping gene and amplification data were used to quantify
the expression of the genes of interest. Relative expression values (2−∆∆Ct) were calculated using Excel
(Microsoft). The unpaired t-test (two-tail) was used to compare the different time points for each gene
investigated (day 0 vs day 15). All data are presented as mean ± standard error of the mean (SEM).
A p-value ≤ 0.01 was deemed statistically significant.
3. Results
3.1. Differentiation of hiPSCs into Cardiomyocytes
Cardiomyocytes were differentiated from hiPSCs, comparing two differentiation protocols,
STEMdiff and CDM3 adapted from [21], using two commercially available patient-derived hiPSC lines:
WTSIi020-A and UKKi025-A, corresponding to a healthy donor and an HCM patient, respectively.
Various differentiation cell batches were produced to optimize the protocol for our study (see Table 3).
Cardiac differentiation was induced in both lines with the results showing that the production of
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hiPSC-CMs using the STEMdiff protocol exhibited high variability, while the CDM3 protocol was found
to be more stable and effective, especially when started at a cell passage number >40 and at higher
than 85% cell confluency (Figure 1 and Table 3). The quality of our hiPSC-CMs was assessed by visual
inspection of their morphology and beating intensity at harvesting day. Both WTSIi020-A derived
CMs (WTSI-CMs) and UKKi025-A derived CMs (UKK-CMs) obtained from five differentiation batches
were frozen and banked to assess their survival after thawing. WTSI-CMs and UKK-CMs obtained
using the STEMdiff protocol showed low cell recovery post-thawing (10–20% survival), while the ones
differentiated according to the CDM3 protocol displayed better cell recovery post-thawing (40–50%),
when using the freezing media as suggested by the protocols. To improve recovery post-thawing,
another freezing medium, normally used for hiPSC cryopreservation (CryoStor), was tested, which
improved the cell recovery of CMs differentiated in CDM3 up to 60–70% post-thawing.
Table 3. Differentiation protocol comparison. The STEMdiff and CDM3 protocols were compared to
differentiate cardiomyocytes (CMs) using two hiPSC-lines, one from a healthy patient (WTSIi020-A) and
another from a hypertrophic cardiomyopathy patient (UKKi025-A). In terms of cell quality, the CDM3
protocol proved to be better for the differentiation of WTSIi020-A and UKK025-A into CMs.
WTSIi020-A UKKi025-A
Batch No. Protocol Passage Confluence CMs Quality Passage Confluence CMs Quality
1st STEMdiff 38 95% Low 42 95% Mid
2nd STEMdiff 39 95% Differentiation Failed 41 95% Mid
3rd
STEMdiff 39 95% × 41 95% ×
CDM3 39 85% Mid 41 85% High
4th CDM3 40 85% High 41 90% High
5th CDM3 42 90% High 42 95% High
value ≤0.01 was 
−ΔΔCt
value ≤0.01 was deeme  stati tically significant.
Figure 1. Illustration of hiPSC differentiation with Chemically-Defined Medium 3 (CDM3) protocol
adapted from Burridge et al. [21].
3.2. Characterization of hiPSC-CMs
The robustness of the selected differentiation protocol (CDM3) was assessed in terms of proportion
of differentiated to undifferentiated cells in the population, by performing flow cytometry using
cardiac and pluripotency markers. Cardiac-specific troponin (TNNT2) was used to specifically label
differentiated CMs [21,30], and octamer-binding transcription factor 4 (OCT4) [31] was used to check
for the presence of undifferentiated hiPSCs. Flow cytometry analysis was performed on sampled cells
from the fifth differentiation batch on day 0 and day 15. The efficiency of the CDM3 protocol for both
hiPSC lines was demonstrated by the finding that 75% of WTSI-derived cells and 97% of UKK-derived
cells were positive for cardiac troponin at day 15 (Figure 2A,B). The fluorescence intensities of TNNT2+
and OCT4+ cells on day 0 and 15 were measured and the median fluorescence intensities (MFI) were
calculated (Figure 2C,D). The data showed a decrease in the number of OCT4+ cells from day 0 to day
15, while a significant increase in TNNT2+ cells occurred over time, which underlines the robustness of
the differentiation protocol and indicates high cell purity for both WTSI-CM and UKK-CM populations.
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Figure 2. Characterization of cardiomyocytes derived from WTSIi020-A and UKKi025-A. (A,B) Flow
cytometry analysis of cells positive for TNNT2 and OCT4 at the beginning (day 0) and the end (day 15)
of differentiation in CDM3. (C,D) Median fluorescence intensities of TNNT2+ and OCT4+ populations
at day 0 and 15 of the CDM3 protocol. n = 3 biological replicates. (E,F) Heatmap plots representing
RT-qPCR for markers of pluripotency (NANOG, OCT4, SOX2, KLF4, MYC), cardiac progenitors
(NKX2.5) and cardiomyocytes (TNNT2, MHY6, MHY7) on day 0 and day 15. n = 3 independent
biological replicates performed in technical triplicates. (G) Immunofluorescent staining images of
cardiomyocytes derived from WTSIi020-A and UKKi025-A. WTSIi020-A CMs show clear formation of
immature sarcomeric-like structure while UKKi025-A CMs display a disrupted structure and rather
enlarged cell morphology (marked with *). Significance level A: **** poct4 < 0.001; * ptnnt2 < 0.023;
B: *** poct4 = 0.0002; **** ptnnt2 < 0.0001; C: ** poct4 = 0.0015; **** ptnnt2 < 0.0001; D: * poct4 = 0.0142;
**** ptnnt2 < 0.0001; E: p ≤ 0.0001; F: p ≤ 0.0002.
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The fifth batch cells were also sampled and examined for pluripotent and cardiac gene patterns
(Day 0 vs Day 15), comparing them with a commercially available cardiomyocyte line, Cor.4U-CMs,
by real-time quantitative PCR (RT-qPCR) (Figure 2E,F). In concordance with previously reported
patterns [21,32], the pluripotency markers Nanog Homeobox Protein (NANOG), OCT4 and SRY
(Sex determining Region Y)-box 2 (SOX2) were found to have been down-regulated on day 15 when
compared to day 0, meaning that the pluripotent state, normally maintained in undifferentiated cells
by a complex network made of these transcription factors, was diminished [31]. The expression
level of tumorigenic markers Kruppel Like Factor 4 (KLF4) and V-Myc Avian Myelocytomatosis Viral
Oncogene Homolog (MYC) [33] resulted in a significant decrease at day 15, indicating an absence of
carcinogenicity in the differentiated populations [34]. As expected, cardiac-specific markers such as
NKX2.5, TNNT2, MYH6 and MYH7 were found completely absent on day 0 while highly expressed on
day 15. Surprisingly, the cardiac progenitor NK2 Homeobox 5 (NKX2.5), cardiac troponin T2 (TNNT2),
embryonal myosin heavy chain (MYH6) and adult myosin heavy chain (MYH7) were found to have
similar expression levels in both hiPSC-CM populations. This could be related to the cardiomyocyte
maturity status. Indeed, NKX2.5 and MHY6 are normally highly expressed during CM differentiation
and myofilament establishment, the latter of which introduces contractile capacity in the cells [35].
The contraction-relaxation cycle promotes the maturation of fetal/immature CMs [28,36]. Mature
CMs should display a high level of MYH7 and low or no MYH6 expression. TNNT2 is expressed in
both immature and mature CMs, with the difference being that in mature cells its expression level is
somewhat constant and stable [37]. The above-mentioned gene expression results indicate that our
day 15 WTSI-CMs and UKK-CMs, differentiated in CDM3 medium, were still immature.
In concordance with the gene expression results, immunofluorescent staining images (Figure 2G)
showed clear formation of immature sarcomeric-like structures in WTSIi020-A CM, while UKKi025-A
CM exhibited discontinued actin filament fibers and a rather enlarged cell morphology. The beating
patterns of these two types of cardiomyocytes also differed, in that the UKKi025-A CMs (Supplementary
Video S1B) displayed arrhythmic beating as opposed to the WTSIi020-A CMs (Supplementary Video S1A).
3.3. Generation of Triculture Cardiac Organoids
In a next step, highly contractile cardiac organoids—composed of hiPSC-CMs, primary human
cardiac microvascular endothelial cells (HCMECs) and primary human cardiac fibroblasts (HCFs)—were
generated, using Terasaki plates in a modified hanging drop approach [5,29]. 25 µL of the cell mixture
were pipetted onto each Terasaki well, inverted and incubated for at least three days, until organoids
were formed. The cell seeding density was optimized at 100,000 cells per organoid and the cell ratio
was 3:5:2, i.e., three parts CMs, five parts endothelial cells and two parts fibroblasts, mimicking adult
human heart tissue, as previously described by Devalla and Passier [28].
3.3.1. Proof of Concept Experiment: Gold Standard Cor-Oids
To validate the triculture approach, the organoid formation concept was initially tested and
confirmed by generating contractile cardiac organoids containing commercially available hiPSC-CMs.
Cor.4U-CMs were tricultured together with the HCMECs and HCFs. The Cor.4U-based organoids
(referred to as Cor-Oids) were chosen as a positive control for comparison to organoids containing our
differentiated hiPSC-CMs.
On day 3 after triculture seeding, the Cor-Oids were harvested from the Terasaki plates and
transferred onto Poly-L-Lysine pre-coated plates (Figure 3A) to prevent complete attachment and
spreading on the bottom of the well plate. They were then maintained in culture until day 21 (D21),
when they showed an increased contraction activity compared to the harvesting day (D3). On day 21,
the Cor-Oids shrunk in dimension, assuming a compact and well-defined spherical shape, showing
significantly increased beating intensities.
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Figure 3. Modelling Adult Human Heart Organoids. (A) Generation of contractile cardiac organoids
(Cor-Oids) containing Cor.4U-CMs, HCMECs and HCF at 3:5:2 cell ratio using Terasaki plates showed the
formation of compact ball-like shapes after 21 days of culture. (B) Immunofluorescence staining images
of Cor-Oids after 14 days of culture, labelled with cardiac-specific troponin (TNNT2), vascular cadherin
(VeCADH) and vimentin (VIM), showing organoids with a lack of defined cardiac structures (T-tubules
and sarcomeres). (C) Immunofluorescence staining images of Cor-Oids after 21 days of culture, labelled
with cardiac-specific troponin (TNNT2), vascular cadherin (VeCADH) and vimentin (VIM), showing
CMs migration toward the organoid core, promoting the formation of cardiac filament-like structures.
Scale bars = 200 µm.
The cell distribution and the structural integrity of the Cor-Oids were analyzed and confirmed via
immunofluorescence staining for cell-specific markers after 14 and 21 days post-seeding, using TNNT2,
VeCADH and VIM as specific markers for CMs, HCMECs and HCFs, respectively. All expected cell
types were positively identified within the organoids. The CMs showed a preference to localize at
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the organoids’ perimeter, while HCMECs and HCFs were localized predominantly in the inner part,
on day 14 (Figure 3B).
Interestingly, a more prominent CM migration to the organoids’ core was observed in day 21
Cor-Oids (Figure 3C), implying that one additional week of culture appears to be advantageous for
cell distribution and migration. A more evenly distributed cell pattern was evident, and the CMs (red)
formed an interlaced filament-like structure all around the perimeter of the Cor-Oids (Figure 3C).
We have shown that a triculture approach is effective in forming cardiac organoids composed
of physiological and cardiomyopathic hiPSC-CMs. We observed that the longer the triculture
period, the more contact between myocytes and nonmyocytes was established, thus generating
more physiological-like cardiac organoids. We conclude that day 14 Cor-Oids were decidedly less
physiological than their day 21 counterparts, and we set the latter as the experimental standard for the
further generation of organoids containing our hiPSC-CMs.
3.3.2. hiPSC-CM-Based Cardiac Organoids
Following the optimization of the Cor-Oids protocol, in a next step, both the WTSI-CMs and
UKK-CM cell lines were used for the generation of organoids. A single cell suspension of either cell type
was mixed with both HCMECs and HCFs (3:5:2, 100,000 cells/organoid) to establish organoids representing
healthy and HCM cardiac tissue. We named these organoids WTS-Oids and UKK-Oids, respectively.
The WTS-Oids and UKK-Oids were also maintained for 21 days, and evaluated in terms of
cell distribution, migration of CMs towards the organoids’ core and the presence of cardiac-like
structures. Immunofluorescence staining of TNNT2, VeCADH and VIM performed on WTS-Oids
and UKK-Oids was compared to Cor-Oids at day 21. The HCMEC and HCF cellular distribution
were found to be similar in all organoid types (Figure 4A–C, iii–iv). However, several differences
were observed regarding the hiPSC-CMs of alternative origin. The CMs in the WTS-Oids were
clearly distributed around the perimeter, forming a unique filament-like structure (red staining,
Figure 4B, i–ii), while in the UKK-Oids (Figure 4C, i–ii) the formation of a filamentous structure was
still in progress. These findings demonstrated that the patient-derived CMs initially form a filamentous
structure on the organoids’ perimeter and then migrate to the core, promoting the formation of cardiac
filament-like structures (T-tubules and sarcomeres). We speculate that this migration enhances the
physiological-like properties of the organoids. However, our findings also indicate that the WTS-Oids
were less physiological when compared to the Cor-Oids (Figure 4A, i–ii) and the UKK-Oids appeared
to exhibit the least physiological-like properties at 21 days.
These findings may suggest that the expression of the organoids’ physiological-like properties
depend on the source of CMs. To assess this further, the first day of contractions and relaxations
and the beating time of each organoid type were recorded and compared over 21 days of culture
(Table 4). Our data showed that contractions and relaxations (beating cycles) represent a conditioning
of the organoids, which enhances the formation of cardiac-like structures and promotes the organoids’
physiological properties over time. Cor-Oids exhibited the longest sustained beating times among the
three organoid groups, while WTS-Oids showed intermediate and UKK-Oids the shortest sustained
beating times.
Table 4. The organization of organoids depends on their sustained beating time.
Organoid Type Visible Contractions and Relaxations Sustained Beating Time
Cor-Oids Day 2,3 ~3 Weeks
WTS-Oids Day 7,8 ~2 Weeks
UKK-Oids Day 12–15 ~1 Week
Over 21 days of culture, the day when contractions and relaxations were recognized and the sustained beating
time of each organoid type were found to be key points for determining their structural organization. Indeed,
contractions and relaxations over time stimulate the formation of defined cardiac-like structures.
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Figure 4. Determining the structural development of cardiac organoids. (A–C) Immunofluorescence
images of Cor-Oids, WTS-Oids and UKK-Oids after 21 days of culture, labelled with cardiac-specific
troponin (TNNT2), vascular cadherin (VeCADH) and vimentin (VIM). We identified similar structural
patterns (A–C, iii–iv) in all organoid types, in terms of HCMEC (magenta) and HCF (green) distribution.
Different structural development patterns were observed regarding the migration of hiPSC-CMs and the
formation of cardiac filament-like structures (red), which were well-defined in Cor-Oids (A, i–ii), mostly
perimetric in WTS-Oids (B, i–ii), and still in formation in UKK-Oids (C, i–ii). Scale bars = 200 µm.
3.3.3. Cardiac Organoids Display Patient-Specific Phenotypic Features
In order to further assess the organoids’ beating patterns and frequencies, a calcium ion binding
dye was used to determine their calcium activity after 21 days of culture. As expected, phenotypical
differences based on the source of hiPSC-CMs were observed. Cor-Oids were found to have a
rhythmically regular beating pattern, with a beating rate of 82 ± 2 bpm (Figure 5A and Supplementary
Video S2A) [38]. Interestingly, the beating pattern of WTS-Oids was found to be regular, but with
a much slower rate (31 ± 2 bpm) compared to Cor-Oids, which may be due to the fact that the
WTSIi020-A-CMs were not sorted for cell purity (Figure 5B and Supplementary Video S2B). Notably,
UKK-Oids presented with an irregular beating pattern and a variable beating rate (52 ± 8 bpm), which
may correspond to the arrhythmia typically observed in HCM patients (Figure 5C and Supplementary
Video S2C) [17]. Our findings confirm that the physiological-like state of the organoids is highly
dependent on the culture time.
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Figure 5. Patient-specific (patho-)physiological features mirrored by cardiac organoids. (A–C) Analysis
of the beating patterns and rates of Cor-Oids, WTS-Oids and UKK-Oids on day 21 (A) Cor-Oids showed
a regular beating pattern with a beating rate of 82 ± 2 bpm (B) WTS-Oids showed a similar regular
beating pattern, but a slower beating rate than Cor-Oids (C) UKK-Oids presented an arrhythmic beating
pattern and a significant variability in their beating rate. RFI = Relative Fluorescence Intensity.
4. Discussion
Cardiomyopathies are a subset of human cardiovascular diseases, which are currently among
the leading cause of morbidity and mortality worldwide [5,30]. Although classified into one group,
cardiomyopathies present with many differences in terms of disease mechanisms, which renders
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diagnosis complex and makes it difficult to establish a uniform therapeutic approach [2]. Generally,
cardiomyopathies affect the function of the heart due to compromised CM morphology and
physiology [39,40]. Unexpected pharmaco-related side effects and toxicities have led to serious
outcomes, such as myocardial infarction and the development of chronic heart failure [22,33]. Moreover,
the discovery of novel pharmaceutical lead compounds is not only a long and expensive process but is
often compromised by drug efficacy and drug safety problems in clinical trials [12]. It is thus of great
importance to improve and accelerate the drug discovery process by establishing a human-relevant
tissue model, capable of representing human physiological functions in vitro. Organoids may embody
the most tangible solution to evaluating drug safety during the early phase of preclinical drug discovery,
allowing for the development of risk mitigating strategies by testing patient-specific responses and
tailoring more precise treatments [12,39,41]. Indeed, conventional 2D cell culture has significant
shortcomings, thereby limiting its relevance in assessing drug safety and efficacy [42]. Some previously
established cell culture models using isolated CMs from animals showed their nonrelevance for human
translation [40,43]. Models based on human cardiac cell lines were found to be too simplistic and poor
in the representation of physiological or pathological states [44]. Previous cardiac organoid models
did neither include endothelial cells as a nonmyocyte component in the microtissues, nor contain
cardiomyocytes derived from hiPSC lines having a known cardiac disease background [43,45].
Our study aims to elucidate the suitability of cardiac organoids as a novel in vitro model for
genetically healthy and hypertrophic cardiomyopathy (HCM) heart conditions. This model could serve
as a platform for understanding disease mechanisms as well as designing patient-specific treatments.
Making use of the fact that hiPSCs maintain the genotype of the donor, we differentiated CMs from
hiPSCs derived from a healthy patient and an HCM patient in order to assess their capacity to represent
the corresponding human heart (patho-)physiology [16]. After comparing two differentiation protocols
for robustness and efficiency, the protocol developed by Burridge et al. was selected to derive healthy
(WTSI-CMs) and HCM (UKK-CMs) CMs from hiPSCs [21]. We found this protocol to be the most
economical and efficient differentiation protocol for use in the academic lab. The differentiated cells
were characterized by flow cytometry, with the majority of the differentiated cells (day 15) proving
positive for TNNT2, as confirmed by calculating the median fluorescence intensities (MFI) of the
light emitted by TNNT2+ populations. Further characterization was performed examining the gene
expression patterns on both (WTSIi- and UKKi-derived cells) day 15 TNNT2+ populations, showing
downregulation of pluripotency (NANOG, OCT4, SOX2) and carcinogenicity (KLF4, MYC) markers,
which demonstrates high differentiation efficiency and absence of oncogenicity. Cardiac markers
(NKX2.5, TNNT2, MYH6 and MYH7) were found upregulated, which suggests the formation of
advanced cardiac structures. However, the high expression of NKX2.5 and MYH6 indicate that
both day 15 WTSI-CMs and UKK-CMs were still rather immature cardiomyocytes [16]. Once the
differentiation protocol was established, WTSI-CMs and UKK-CMs were used for the generation of
cardiac organoids, which we labelled WTS-Oids and UKK-Oids, respectively. Our aim in performing
triculture cell seeding to establish cardiac organoids is to provide more physiological-like function and
structure in an in vitro model. The triculture cell ratio —consisting of three parts cardiomyocytes, five
parts endothelial cells and two parts fibroblasts —was chosen to resemble the corresponding cell ratio
in the adult human heart [28]. This ratio is, however, highly variable and subject to change, according
to the different developmental stages of the human heart.
To prevent overgrowth of the endothelial cells and fibroblasts, we used a cardiomyocyte
maintenance medium during the triculture organoids culture. In the myocardium, endothelial
cells are known to regulate the contractile state of CMs through autocrine and paracrine signaling
molecules, while fibroblasts play an essential role in the maintenance and remodeling of the 3D
structure through the synthesis of extracellular matrix (ECM) [12,22,28].Therefore, we used a triculture
approach of hiPSC-CMs, HMCECs and HCFs for the generation of highly contractile cardiac organoids,
with the goal of mimicking the cardiac microenvironment as closely as possible in 3D. As a parallel
comparison, commercially available cardiomyocytes Cor.4U-CMs were used to generate what we
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defined as standard organoids (Cor-Oids). The Cor-Oids exhibited more physiological-like properties
than the hiPSC-derived organoids after 21 days in culture, exhibiting sustained beating, which may
indicate that extended myocyte and nonmyocyte cell-to-cell contact may promote the formation of
more physiological cardiac-like structures.
Cell distribution, CM migration, appearance of cardiac structures and beating patterns as well as
beating rates of WTS-Oids and UKK-Oids were compared to the Cor-Oids to evaluate the functional
features and the physiological-like properties at the same timepoint (day 21). We found that CM
distribution is dependent on organoid culture time to allow for the migration of CMs towards the
core of the 3D microenvironment. This migration promotes the interaction of CMs with nonmyocytes,
leading to the formation of filamentous-like structures, which most likely represent T-tubules and
sarcomeres. Moreover, we observed that the appearance of the beating cycle is directly related to
the formation of T-tubules and sarcomeres, which, in turn, is strictly associated with the organoids’
sustained beating time. This may explain why WTS-Oids and UKK-Oids show weaker beating,
and hence less physiological-like properties, when compared to Cor-Oids. Finally, we observed that
WTS-Oids present a rhythmic regular beating pattern while UKK-Oids present with arrhythmia, which
is typical for HCM patients. This suggests that organoids retain the phenotype of the hiPSC donor.
Taken together, the proposed in vitro organoid model may represent a physiological-like human
heart mini-tissue, which retains the geno- and phenotypical characteristics of the corresponding donor
tissue. Therefore, our organoids may represent a robust model system, suitable for medium- to
large-scale production, for studying and modeling cardiac disease. Feasibility assays for producing
organoids in a more size-controlled, automated and high-throughput fashion is envisioned. It should
be noted that this system cannot entirely replace animal models due to the bypassing of critical
composite features of human diseases, such as complex sensory and feedback systems.
We acknowledge that our study has several limitations. Firstly, the question that has to be
addressed in more detail in the future is the maturation of hiPSC-derived CMs. A recent study
suggests that multicellular contact over prolonged culture periods could enhance maturation [46].
Secondly, the observed differences between the hiPSC lines and the organoids need to be investigated
further using a larger quantity of organoids. The mutation in the HCM hiPSC-CMs should be
confirmed by total DNA sequencing. Thirdly, it is understood that modeling cardiomyopathy using the
triculture approach does not account for further influencing factors, such as immunological responses
and additional cardiac cell fractions (e.g., CM subpopulations like Purkinje fibers). Immune cells
could ideally be cultivated on the outer layer of the organoids to monitor immunological responses.
It would be insightful to elucidate immune cell migration patterns in the rather loose-structured,
cardiomyopathy-representing organoids. Finally, it would be ideal to derive all organoid cell fractions
from the identical parental hiPSC line for the triculture approach. There exist established protocols to
derive hiPSCs into endothelial cells and cardiac fibroblast [47,48]. We suggest that the recapitulation
of cardiomyopathic properties in such organoids could be even more pronounced, especially in
diseases where the pathophysiology does not solely stem from cardiomyocytes pathology but also
from nonmyocyte components.
5. Conclusions
In the present study, we demonstrate the differentiation of isogenically comparable hiPSC lines
into cardiomyocytes from a healthy human donor and a patient with hypertrophic cardiomyopathy
for the generation of human cardiac organoids. To mimic adult human heart tissue, healthy and
HCM-associated hiPSC-CMs were combined with HCMECs and HCFs to generate highly contractile
triculture organoids. These organoids are capable of representing significant phenotypical features of
the healthy and hypertrophic cardiomyopathic human heart in vitro.
Obtaining hiPSCs, reprogrammed from patient-derived somatic cells, offers not only the possibility
of differentiating all cell types involved in the generation of highly contractile cardiac organoids but
may open up new perspectives for the development of safer and more efficacious patient-tailored
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therapeutic strategies. Our novel cardiac organoids may, therefore, represent a valuable platform for
high-throughput testing and validation of novel therapeutic agents to treat cardiomyopathy.
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HCFs human cardiac fibroblasts
HCM hypertrophic cardiomyopathy
HCMECs human cardiac microvascular ECs
hiPSCs human induced pluripotent stem cells
hiPSC-CMs hiPSC-derived CMs
KLF4 kruppel like factor 4
MFI median florescence intensity
MYC V-Myc avian myelocytomatosis viral oncogene homolog
MYH6 myosin heavy chain 6
MYH7 myosin heavy chain 7
NANOG nanog homeobox protein
NKX2.5 NK2 homeobox 5
OCT4 octamer-binding transcription factor 4
RT-qPCR real time quantitative PCR
SOX2 SRY (sex determining region Y)-box
TNNT2 cardiac-specific troponin
UKK-CMs UKKi025-A derived CMs
UKK-Oids UKK-CMs based organoids
VeCADH vascular cadherin
VIM vimentin
WTSI-CMs WTSIi020-A derived CMs
WTS-Oids WTSI-CMs based organoids
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